Hopstem Biotech Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $29.6M

  • Investors
  • 14

Hopstem Biotech General Information

Description

Developer of neural cell therapy products designed for the treatment of chronic brain injuries. The company's technology utilises a proprietary differentiation platform to produce allogeneic forebrain neural progenitor cells from induced pluripotent stem cells, enabling healthcare providers to promote neural circuit reconstruction and restore motor function in patients with neurological disorders.

Contact Information

Website
www.hopstem.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 11, Phase 5, Heda Pharmaceutical Valley
  • Qiantang District
  • Hangzhou, Zhejiang 310018
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • Building 11, Phase 5, Heda Pharmaceutical Valley
  • Qiantang District
  • Hangzhou, Zhejiang 310018
  • China
+86 0571

Hopstem Biotech Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hopstem Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series C) 10-Aug-2026 $29.6M Completed Generating Revenue
9. Secondary Transaction - Private 04-Jul-2024 Completed Generating Revenue
8. Secondary Transaction - Private 08-Dec-2022 Completed Generating Revenue
7. Secondary Transaction - Private 13-Dec-2021 Completed Generating Revenue
6. Early Stage VC (Series B) 31-Oct-2021 Completed Generating Revenue
5. Early Stage VC (Series A2) 28-May-2021 Completed Pre-Clinical Trials
4. Early Stage VC (Series A1) 09-Dec-2020 Completed Pre-Clinical Trials
3. Secondary Transaction - Private 26-Jun-2019 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 24-Dec-2018 $1.76M Completed Pre-Clinical Trials
1. Seed Round 17-Jul-2017 $1.76M $1.76M Completed Startup
To view Hopstem Biotech’s complete valuation and funding history, request access »

Hopstem Biotech Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Guangzhou Health Industry Investment Private Equity Fund Management Growth/Expansion Minority
HaiBang Ventures Venture Capital Minority
Tasly Capital Corporate Venture Capital Minority
Hillhouse Investment Group PE/Buyout Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial

Hopstem Biotech FAQs

  • When was Hopstem Biotech founded?

    Hopstem Biotech was founded in 2017.

  • Where is Hopstem Biotech headquartered?

    Hopstem Biotech is headquartered in Hangzhou, China.

  • What industry is Hopstem Biotech in?

    Hopstem Biotech’s primary industry is Drug Discovery.

  • Is Hopstem Biotech a private or public company?

    Hopstem Biotech is a Private company.

  • What is Hopstem Biotech’s current revenue?

    The current revenue for Hopstem Biotech is .

  • How much funding has Hopstem Biotech raised over time?

    Hopstem Biotech has raised $78M.

  • Who are Hopstem Biotech’s investors?

    Guangzhou Health Industry Investment Private Equity Fund Management, HaiBang Ventures, Tasly Capital, Hillhouse Investment Group, and LAV (Lilly Asia Fund) are 5 of 14 investors who have invested in Hopstem Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process